Viatris Is Buying a Pain Business to Make Its Growth Story True

A $1.65B bet on EXPAREL, a guidance raise that still halves the growth rate, and the HRT patch boom management keeps re-explaining

VTRS · Earnings Call · 2026-11-05

The raise that halves the number

Viatris raised the midpoint of every 2026 guidance metric on this call. That is the headline. The arithmetic underneath is less flattering: the raised midpoint implies roughly 2% operational revenue growth for the year, against the ~3% the company guided in February. Through nine months, revenue grew 2% operationally, adjusted EBITDA 6%, adjusted EPS 8% — a genuinely good shape for a company whose revenue peaked at $7.3 billion in 2021 and has since halved. But the CEO framed it as something larger: “we believe we've entered a new phase of sustained growth for Viatris” — Scott Smith, CEO · 2026-11-05. He said close to the same thing in February: “we are confident that we are at the beginning of a period of sustained revenue and earnings growth for the company” — Scott Smith, CEO · 2026-02-26. Three quarters of repetition is not a fresh inflection — it is a management cadence. The keyword history bears that out: updated guidance only ranks second this quarter, behind something far more specific. The something specific is the patch. Estradiol patch products sits atop this quarter's company keywords and shows up as one of the biggest momentum gainers of the period — a rare, company-unique theme rather than generics boilerplate. Gross margin came in at 58% adjusted, and inside the mix, higher-margin North America (up ~7%) and Greater China (up ~10%) more than offset supply-constrained low-margin generics. Adjusted numbers look healthy; the GAAP operating line was still negative in the most recent filed quarter, which is the permanent tension in this equity story.

EXPAREL: the first thing Viatris has ever bought that can lose exclusivity

For a company whose identity is complex generics and portfolio pruning, the Pacira deal is a genuine strategic turn. $36.50 a share, ~$1.65 billion, tender launched October 30, closing expected before month-end. Two patent-protected US products, EXPAREL and ZILRETTA, at margins well above company average, taking a stated US innovative medicines business above $1 billion of revenue in 2027, plus more than $50 million of annual cost synergies by end-2028. The oddity: Viatris is buying an asset with a dated cliff. Paul Campbell was explicit — “we do expect continued growth in EXPAREL until the volume limited generic entry in '30” — Paul Campbell, Interim CFO · 2026-11-05 — and the keyword generic entry appears in this company's vocabulary for essentially the first time. That is a different risk shape than anything in Viatris's history: it is now the owner of a brand whose defence is intellectual property, not manufacturing cost. Four analysts pressed on that durability, and the CEO declined all of them with the same construction — “we don't own Pacira at this point in time nor do we own EXPAREL. So I'm not going to get into specific strategies” — Scott Smith, CEO · 2026-11-05. That is legally correct and strategically empty. The tell is that the company bought its way into a non-opioid pain franchise precisely so it can launch fast-acting meloxicam (PDUFA December 27, launch early 2027) with a sales force it does not currently own.

if you take a look at the momentum in the business and Pacira and other things... the numbers you're talking about are certainly in the ballpark of where we may be going
Scott Smith, CEO · 2026-11-05

That answer to Umer Raffat's question — could $5 billion of EBITDA arrive in 2027 rather than 2030 — is the closest thing to a forward number anyone got. Note what has quietly disappeared: the enterprise-wide strategic review. In Q1 it was the centrepiece, with net savings quantified at $400 million net by 2028 and phased “roughly 30% in '26 an additional 30% in '27 and then the remaining approximately 40% in 2028” — Theodora Mistras, CFO · 2026-02-26. This quarter it collapses to a single sentence about being on track for $120 million this year. What management stops emphasising matters.

Patches, provinces and a plant

The HRT patch surge is the most interesting organic fact in the call, and it is now three quarters old. The mechanism is not generic: removal of the black box warning, plus GLP-1-driven delayed gastric emptying pushing patients toward transdermal delivery. Corinne Le Goff quantified it — 45 million symptomatic US women, under 30% treated, “our patches, we expect that they are going to reach 1.5 million women this year in '26, and we're going to add in '27 another 1 million of women” — Corinne Le Goff, Chief Commercial Officer · 2026-11-05. In August they were fulfilling roughly 70% of orders. This is a supply problem masquerading as a demand problem, and management is throwing capital at it: 24/5 to 24/7 plant utilisation, a new packaging line, sourcing beyond Vermont. The offset is familiar. Nashik went from pending classification to Official Action Indicated in September, and manufacturing was suspended in October. That is ~$100 million of Q3 revenue and another ~$100 million guided for Q4 — the third consecutive facility-remediation narrative, following Indore. Emerging markets and JANZ are now both guided to low-single-digit declines. China, meanwhile, decelerates deliberately: 16-17% in H1, 10% in Q3, below 10% in Q4, low-to-mid single digit in 2027 as hospital procurement policy rolls through 31 provinces.

The tape already agrees

GLP 1 exposure is the other live thread — first-to-file on the semaglutide 25mg tablet, plus presentations for tirzepatide, aimed squarely at the US. That rhymes with the global tape, where GLP-1-adjacent names have led: GLP-1 medication and oral GLP-1s both score among the strongest 90-day advancers in the global keyword set. It is the one place where Viatris is riding a wave rather than describing one. The stock has noticed something. 10.4x free cash flow after a 17% advance in 90 days, versus a share price still 75% below its 2015 peak. Net debt of roughly $12.3 billion against guided gross leverage of 2.9x, inside the 2.8-3.2x target, with $814 million of quarterly free cash flow and $717 million already returned this year. The re-rating is real. The question is whether a company that has now raised guidance three times on a 2% revenue base, bought a branded pain asset with a 2030 cliff, and quietly de-emphasised its own cost programme is genuinely re-based — or simply having its best patch year.